SELLAS Life Sciences Group, Inc. (SLS) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
Times Square Tower
New York City, NY 10036
United States of America (the)
Phone
646 200 5278
Sector
Healthcare
Industry
Biotechnology
Employees
15
First IPO Date
March 12, 2008
| Name | Title | Pay | Year Born |
| Angelos Stergiou | Founder, President, Chief Executive Officer & Director | 1.07M | 1976 |
| John Thomas Burns | Senior Vice President & Chief Financial Officer | 630,592 | 1985 |
| Dragan Cicic | Senior Vice President & Chief Development Officer | 662,734 | 1963 |
| Andrew Elnatan | Senior Vice President of Regulatory Affairs, CMC & Quality | 0 | N/A |
| Stacy Yeung | VP, General Counsel & Corporate Secretary | 0 | N/A |
SELLAS Life Sciences Group, Inc. operates as a late-stage biopharmaceutical entity, dedicated to advancing novel cancer immunotherapies for various cancer indications across the United States. Its primary investigational product, galinpepimut-S (GPS), is a cancer immunotherapeutic agent engineered to target Wilms tumor 1. GPS is currently in Phase III clinical trials for acute myeloid leukemia and Phase 1/2 studies for ovarian cancer. Additionally, the company is progressing nelipepimut-S, an immunotherapy aimed at human epidermal growth factor receptor 2, which is undergoing Phase 2b clinical evaluation for early-stage breast cancer. A strategic collaboration with Merck & Co., Inc. is underway to assess GPS in combination with the PD1 blocker pembrolizumab, specifically within a Phase 1/2 clinical trial encompassing up to five distinct cancer indications, including both hematologic malignancies and solid tumors. Founded in 2012, SELLAS maintains its corporate headquarters in New York, New York.